Pronk L - Search Results

1

Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.

Kruijtzer CMF, Verweij J, Schellens JH, Beijnen JH, Pronk L, Bo M, Lustig V, van Tinteren H, Mackay M, Ten Bokkel Huinink WW. Kruijtzer CMF, et al. Among authors: pronk l. Anticancer Drugs. 2000 Apr;11(4):249-55. doi: 10.1097/00001813-200004000-00004. Anticancer Drugs. 2000. PMID: 10898539 Clinical Trial.

2

Emerging drug treatments for solid tumours.

Schellens JH, Pronk LC, Verweij J. Schellens JH, et al. Among authors: pronk lc. Drugs. 1996 Jan;51(1):45-72. doi: 10.2165/00003495-199651010-00005. Drugs. 1996. PMID: 8741232 Review.

3

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.

Pronk LC, Schrijvers D, Schellens JH, de Bruijn EA, Planting AS, Locci-Tonelli D, Groult V, Verweij J, van Oosterom AT. Pronk LC, et al. Br J Cancer. 1998;77(1):153-8. doi: 10.1038/bjc.1998.24. Br J Cancer. 1998. PMID: 9459161 Free PMC article. Clinical Trial.

4

Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.

Pronk LC, Schrijvers D, Schellens JH, de Bruijn EA, Planting AS, Locci-Tonelli D, Groult V, Verweij J, van Oosterom AT. Pronk LC, et al. Semin Oncol. 1998 Feb;25(1 Suppl 2):23-8. Semin Oncol. 1998. PMID: 9535208 Clinical Trial.

5

Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.

Pronk LC, Hilkens PH, van den Bent MJ, van Putten WL, Stoter G, Verweij J. Pronk LC, et al. Anticancer Drugs. 1998 Oct;9(9):759-64. doi: 10.1097/00001813-199810000-00003. Anticancer Drugs. 1998. PMID: 9840720 Clinical Trial.

6

Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.

van Zuylen L, Schellens JH, Goey SH, Pronk LC, de Boer-Dennert MM, Loos WJ, Ma J, Stoter G, Verweij J. van Zuylen L, et al. Among authors: pronk lc. Anticancer Drugs. 1999 Apr;10(4):361-8. doi: 10.1097/00001813-199904000-00003. Anticancer Drugs. 1999. PMID: 10378670 Clinical Trial.

7

Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.

Pronk LC, Stoter G, Verweij J. Pronk LC, et al. Cancer Treat Rev. 1995 Sep;21(5):463-78. doi: 10.1016/0305-7372(95)90030-6. Cancer Treat Rev. 1995. PMID: 8556719 Review.

8

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.

Hilkens PH, Pronk LC, Verweij J, Vecht CJ, van Putten WL, van den Bent MJ. Hilkens PH, et al. Among authors: pronk lc. Br J Cancer. 1997;75(3):417-22. doi: 10.1038/bjc.1997.68. Br J Cancer. 1997. PMID: 9020489 Free PMC article. Clinical Trial.

9

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.

Pronk LC, Schellens JH, Planting AS, van den Bent MJ, Hilkens PH, van der Burg ME, de Boer-Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G, Verweij J. Pronk LC, et al. J Clin Oncol. 1997 Mar;15(3):1071-9. doi: 10.1200/JCO.1997.15.3.1071. J Clin Oncol. 1997. PMID: 9060547 Clinical Trial.

10

The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study.

Pronk LC, van Putten WL, van Beurden V, de Boer-Dennert M, Stoter G, Verweij J. Pronk LC, et al. Cancer Chemother Pharmacol. 1999;43(2):173-7. doi: 10.1007/s002800050880. Cancer Chemother Pharmacol. 1999. PMID: 9923825 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

48 results

Search Page